Analyst Price Targets — NTRA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 5, 2026 2:28 pm | — | Guggenheim | $270.00 | $230.65 | TheFly | Natera price target raised to $270 from $230 at Guggenheim |
| December 22, 2025 11:58 am | — | Canaccord Genuity | $285.00 | $231.96 | TheFly | Natera price target raised to $285 from $260 at Canaccord |
| December 15, 2025 11:27 am | — | Wells Fargo | $205.00 | $231.88 | TheFly | Natera price target raised to $205 from $190 at Wells Fargo |
| December 15, 2025 10:56 am | — | Barclays | $270.00 | $231.88 | TheFly | Natera price target raised to $270 from $230 at Barclays |
| December 1, 2025 9:32 pm | — | Morgan Stanley | $265.00 | $234.25 | TheFly | Natera assumed with an Overweight at Morgan Stanley |
| November 18, 2025 2:33 pm | — | UBS | $280.00 | $213.65 | TheFly | Natera price target raised to $280 from $218 at UBS |
| October 27, 2025 12:46 pm | Navann Ty | BNP Paribas | $172.00 | $192.36 | TheFly | Natera upgraded to Neutral from Underperform at BNP Paribas Exane |
| September 22, 2025 9:35 am | Brandon Couillard | Wells Fargo | $175.00 | $181.11 | TheFly | Natera initiated with an Equal Weight at Wells Fargo |
| September 2, 2025 8:59 pm | Conor McNamara | RBC Capital | $268.00 | $169.34 | TheFly | Natera price target raised to $268 from $255 at RBC Capital |
| August 10, 2025 8:28 pm | Patrick Wood | Morgan Stanley | $195.00 | $151.95 | TheFly | Natera price target raised to $195 from $185 at Morgan Stanley |
Latest News for NTRA
Merit Financial Group LLC lifted its stake in Natera, Inc. (NASDAQ: NTRA) by 32.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,720 shares of the medical research company's stock after acquiring an additional 4,610 shares during the period.
Mirae Asset Global Investments Co. Ltd. reduced its stake in Natera, Inc. (NASDAQ: NTRA) by 21.4% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 51,916 shares of the medical research company's stock after selling 14,100 shares during
William Blair initiated coverage on Natera Inc. (NASDAQ:NTRA), highlighting the company's strong positioning in the emerging minimal residual disease (MRD) testing market and its broader growth outlook driven by multiple business segments.
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today highlighted Allogene Therapeutics' (NASDAQ: ALLO) interim futility analysis from its registrational ALPHA3 trial for cemacabtagene ansegedleucel (cema-cel), an investigational allogeneic anti-CD19 CAR T therapy, in first-line (1L) consolidation large B-cell lymphoma (LBCL). The ALPHA3 trial is…
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today provided an update on a recent decision issued by the United States District Court in the District of Delaware regarding Natera's litigation with ArcherDx and Invitae. In a decision issued on April 6, 2026, the Court ordered an ongoing royalty to Natera of 30% on post-injunction revenues from…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.